Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for atopic dermatitis.
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 550
- Registration Number
- NCT06624228
- Locations
- 🇺🇸
Pa0016 50662, Gilbert, Arizona, United States
🇧🇬Pa0016 40819, Sofia, Bulgaria
🇨🇿Pa0016 40012, Zlin, Czechia
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇫🇷
Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud /ID# 266851, Pierre Benite, Rhone, France
🇫🇷Hôpital Saint Antoine /ID# 265725, Paris, France
🇷🇸General Hospital Djordje Joanovic /ID# 266040, Zrenjanin, Vojvodina, Serbia
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT05995353
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688, Shanghai, Shanghai, China
🇺🇸Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital /ID# 255762, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.